SynthesisJournal of neuro-oncology2025
Diagnostic and predictive molecular biomarkers in brain tumors across the lifespan: an age-stratified consensus statement.
Synthesis in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A novel minimally invasive diagnostic approach of various brain malignancies based on differential miRNA expression.Journal of neuro-oncology · 2026Article
- Advances in Brain Tumor Biomarkers: From Molecular Profiling to Liquid Biopsy and AI-Driven Detection.Cancers · 2026Review
- Artificial Intelligence-Based MRI Segmentation in Glioblastoma and Single Brain Metastasis: An Exploratory Study of Diagnostic and Prognostic Value.Life (Basel, Switzerland) · 2026Article
- Review
- Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1Pharmaceuticals (Basel, Switzerland) · 2026Article
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMolecular profiling has significantly advanced neuro-oncology, enabling the integration of biomarkers into the diagnosis and management of brain tumors. Precision medicine is emerging as a promising strategy; however, the marked heterogeneity of central nervous system tumors results in a low prevalence of actionable targets, limiting clinical applicability. Despite these challenges, ongoing progress in genetics and molecular biology offers new opportunities for targeted therapies. The incidence and clinical relevance of biomarkers vary across tumor types and age groups, reflecting the biological complexity of brain neoplasms throughout life.
methodsA multidisciplinary expert panel conducted a systematic review of the literature and developed a consensus statement addressing key predictive biomarkers across pediatric, adolescent and young adult (AYA), adult, and elderly populations. Evidence was evaluated for diagnostic, prognostic, and therapeutic relevance.
resultsClinical benefit from targeted therapies has been demonstrated for a limited number of alterations, including BRAF p.V600E, NTRK fusions, EGFR, H3 K27M, and IDH1/2 mutations, while several additional biomarkers remain under investigation. The consensus provides an age-stratified overview of these molecular alterations and discusses challenges such as variability in testing approaches, interpretation of variants of uncertain significance, and limited access to comprehensive molecular diagnostics.
conclusionBased on current evidence and expert opinion, the statement highlights the need for age-adapted testing strategies, multidisciplinary molecular tumor boards, and increased clinical trial availability for patients with rare or emerging biomarkers. These recommendations aim to support the implementation of precision medicine and improve outcomes across all age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.